May 17, 2018 | Story Review

Inquirer delivers well-rounded report on using laughing gas for labor pain–except for two things

This story never cites a specific study, nor does it provide links to several existing studies documenting benefits and harms.

4 Star

Laughing gas makes a comeback for women in labor - like Kate Middleton

May 16, 2018 | Story Review

Reuters story on MS drug for kids even less informative than the FDA news release

The story didn’t give a sense of the strength of evidence behind this drug. For example, it didn’t tell readers what the comparison drug was in the trial, nor how many children were in the trial.

2 Star

FDA expands use of Novartis MS drug to pediatric patients

May 11, 2018 | Story Review

Newsweek stokes false hope with ‘cure for baldness’ based on preliminary evidence

The evidence is so scant that readers aren’t likely to get much use out of this story.

3 Star


May 10, 2018 | Story Review

Gene test for depression treatment: Realistic patient story helps keep WSJ article grounded

But the story did not do enough to establish that the research is still preliminary — it has not been published nor peer-reviewed, and everyone is relying on just a little bit of data released by the company.

4 Star

Which Anti-Depressant is Right for You? Your DNA Can Shed Some Light

May 7, 2018 | Story Review

Independent viewpoint helps round out HealthDay story on impact of earlier mammograms

But the story would have been stronger had it described the findings using absolute rather than relative numbers.

4 Star

Earlier Mammograms May Mean Less Need for Aggressive Treatments

May 4, 2018 | Story Review 1

Thank you, New York Times, for asking ‘Who is behind these studies? Where does the money come from?’

The article makes effective use of a question-and-answer format to discuss previous research in this area, and other aspects of the research.

4 Star

Ecstasy as PTSD Relief for Soldiers: ‘I Was Able to Forgive Myself’

May 2, 2018 | Story Review

Another rehashed news release from the Guardian, this time about partial vs. full knee replacement surgery

With no independent reporting, the story glosses over how the study was conducted, what was measured, and what the limitations were.

2 Star

Partial rather than full knee replacements better for many – report

April 30, 2018 | Story Review

In comparison of clot-busting drugs, HealthDay gets props for being clear on costs and harms

On the flipside, it missed significant limitations to the evidence, the most significant one being that there is no evidence that clot-busters save lives in stroke patients.

4 Star

A Better Clot-Buster Drug for Strokes?

April 25, 2018 | Story Review

Guardian spoon-feeds university news release to readers, claiming prostate cancer ‘breakthrough’

This story fails to provide anything more than hyperbole and unsubstantiated claims. Readers deserve more.

1 Star

Prostate cancer breakthrough as UK team develops more accurate test

April 23, 2018 | Story Review

Reuters numbs with numbers on experimental migraine drug

The drug reduced migraines “by at least half in 30 percent of patients who had failed up to four previous treatments,” according to the story. These statistics needed to be explained more clearly.

2 Star

Amgen's Aimovig halved migraine days in 30 percent of trial patients


Tips for Understanding Studies

View More